PROMICEF TAZO is a broad-spectrum veterinary antibiotic therapy designed for dogs and cats, formulated with a powerful combination of Ceftriaxone (third-generation cephalosporin) and Tazobactam (beta-lactamase inhibitor). This synergistic blend enhances antibacterial efficacy against resistant organisms, making it highly effective in the treatment of complex systemic and localized infections.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to essential enzymes (PBPs), leading to bacterial lysis, while Tazobactam protects ceftriaxone from degradation by beta-lactamase enzymes, thereby extending its spectrum of activity.
This injection provides reliable therapeutic outcomes in respiratory, dermatological, urinary, bone and joint, intra-abdominal, and systemic infections, ensuring optimal veterinary care.
(Reviewed and presented by Vɪsʜɴᴜ Dᴜᴛᴛ Tʀɪᴘᴀᴛʜɪ | Pᴇᴛ Exᴘᴇʀᴛ, exclusively on PᴇᴛsLɪғᴇsᴛʏʟᴇ.)
Composition
Each combipack contains:
Indications
PROMICEF TAZO is indicated for the treatment of bacterial infections caused by resistant organisms in dogs and cats, including:
-
Respiratory tract infections
-
Bacterial skin and soft tissue infections
-
Urinary tract infections
-
Bone and joint infections
-
Septicemia and systemic bacterial infections
-
Intra-abdominal infections
-
Meningitis
Benefits
-
Broad-spectrum efficacy against Gram-positive and Gram-negative pathogens
-
Enhanced antibacterial activity due to beta-lactamase inhibition
-
Effective for resistant and complicated infections
-
Suitable for both IV and IM administration in dogs and cats
-
Reliable treatment for both localized and systemic bacterial infections
Dosage and Administration
-
Dogs: 15–50 mg/kg every 12–24 hours (IM/IV)
-
Cats: 25–50 mg/kg every 12 hours (IM/IV)
-
Reconstitute before administration:
-
Use immediately after preparation or as advised by the veterinarian.
-
Dosage is calculated on ceftriaxone equivalence (500 mg ceftriaxone = 562.5 mg ceftriaxone + tazobactam).
Warnings & Precautions
-
Do not use in pets with known hypersensitivity to cephalosporins or tazobactam.
-
For veterinary use only; not for oral administration.
-
Pain may occur at IM injection site; IV use may cause local phlebitis.
-
Monitor liver/kidney function during prolonged use.
-
Avoid concurrent use with aminoglycosides or calcium-containing solutions.
Adverse Reactions
-
Gastrointestinal upset (nausea, vomiting, diarrhea)
-
Hematological changes (eosinophilia, thrombocytosis, leucopoenia)
-
Elevated liver enzymes, creatinine, and BUN levels in rare cases
-
False-positive Coombs’ and urine glucose test possible
Storage
Presentation
-
Vial containing: Ceftriaxone 500 mg + Tazobactam 62.5 mg (powder)
-
Ampoule: 5 ml sterile water for injection
-
Syringe and needle provided in pack
Manufacturer
SAVA HEALTHCARE LIMITED
Plot No. 507-B to 512, GIDC Estate, Wadhwan City – 363035,
Surendranagar, Gujarat, India
